Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

At Least 1 Year on Bisphosphonates Needed for Fracture Prevention

Lisa Rapaport  |  December 14, 2021

(Reuters Health)—It takes 12.4 months of bisphosphonate therapy to prevent one nonvertebral fracture per 100 postmenopausal women with osteoporosis, a meta-analysis of randomized clinical trials suggests.1 Researchers examined data on 10 randomized clinical trials with a total of 23,384 women who had an osteoporosis diagnosis based on either existing vertebral fractures or a bone mineral…

FDA Authorizes New Long-Acting, Monoclonal Antibodies for Pre-exposure Prevention of COVID-19 in Certain Individuals

U.S. Food & Drug Administration   |  December 13, 2021

On Dec. 8, the U.S. Food & Drug Administration (FDA) issued an emergency use authorization (EUA) for AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab and administered together) for the pre-exposure prophylaxis (prevention) of COVID-19 in certain adults and pediatric individuals (12 years of age and older weighing at least 40 kilograms [about 88 pounds]). The product…

Therapeutics for COVID-19: An update from ACR Convergence 2021

Lara C. Pullen, PhD  |  December 10, 2021

ACR CONVERGENCE 2021—Rheumatology patients who test positive for COVID-19 would benefit from early use of monoclonal antibodies, said Luis Ostrosky-Zeichner, MD, chief of the Division of Infectious Diseases, McGovern Medical School, University of Texas Health Science Center (UTHealth), Houston, in a session about effective treatment options for COVID-19. Acknowledging that the SARS-CoV-2 virus has already…

Congress Acts to Avert Nearly 10% Cut to Medicare Reimbursement Set for 2022

From the College  |  December 10, 2021

Updated Dec. 16, 2021: In response to advocacy from the ACR and other provider and patient groups, Congress passed legislation to avoid the nearly 10% “Medicare cliff” scheduled to take effect Jan 1. The ACR thanks all ACR/ARP members and patients who took the time to engage in this critical effort with us to protect…

Care of Patients with Spondyloarthritis

Lara C. Pullen, PhD  |  December 9, 2021

At the ACR Convergence session CARE: Spondyloarthritis, Alexis Ogdie, MD, presented key principles of diagnosis & management of patients with spondyloarthritis.

Research on SLE, pJIA & More Highlighted in 2nd ACR Convergence 2021 Plenary Session

Samantha C. Shapiro, MD  |  December 9, 2021

Experts shined a spotlight on select abstracts of the latest rheumatology research, addressing such topics as racial disparities in the management of children with SLE, vitamin D or fish oil supplementation to prevent autoimmune disease & more.

Pediatric Rheumatology Year in Review, 2021: Basic Science

Elizabeth Sloan, MD  |  December 9, 2021

ACR Convergence 2021—The field of pediatric rheumatology has benefited from significant developments in the basic and translational sciences over the past year, and it can be challenging to keep up with the latest discoveries. In the Basic Science section of the Pediatric Rheumatology Year in Review at ACR Convergence, Tiphanie Vogel, MD, PhD, assistant professor…

Cardiovascular Risks & Insights from ACR Convergence 2021

Thomas R. Collins  |  December 9, 2021

Experts share insights into how LDL & HDL levels are affected by inflammation & the treatment of rheumatic disease, addressing how targeting these levels may improve cardiovascular outcomes for patients.

New Findings on COVID-19 Vaccination, Race & More Shared in 1st Plenary Session

Thomas R. Collins  |  December 9, 2021

Researchers shared findings on the immune response to COVID-19 vaccination in immunocompromised patients, insights into cognitive impairment in SLE & more.

Does Switching from IV to Subcutaneous Tocilizumab Affect RA Disease Flare?

Michele B. Kaufman, PharmD, BCGP  |  December 9, 2021

Researcher identified multiple factors for flare, including non-use of methotrexate, in patients with rheumatoid arthritis who had switched from intravenous (IV) tocilizumab to subcutaneous tocilizumab.

  • « Previous Page
  • 1
  • …
  • 118
  • 119
  • 120
  • 121
  • 122
  • …
  • 816
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences